Pacific Biosciences of California Stock News

MENLO PARK, Calif., Feb. 25, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee

Pacific Biosciences of California Inc. (NASDAQ:PACB) has a beta value of 1.35 and has seen 8.43 million shares traded in the last trading session. The company, currently valued at $2.43B, closed the last trade at $11.47 per share which meant it gained $0.44 on the day or 3.99% during that session. The PACB stock price Pacific Biosciences of California Inc. (PACB) Suffers From Weak Fundamental Momentum Read More »

PacBio (PACB) sees strength in Q4 segmental revenues, led by robust consumable and instrument sales.

Pacific Biosciences (PACB) has lost ~10% in the pre-market on Wednesday after several Wall Street analysts slashed their price targets on the life sciences company in reaction to…

PacBio HiFi Sequencing Technology Will Be Used to Investigate Effect on Diagnostic Yield of Unresolved Rare Diseases in Children PacBio HiFi Sequencing Technology Will Be Used to Investigate Effect on

Futures Tread Water Ahead Of FOMC Mintues As Russia Forgets To Invade Ukraine The global rally stalled on Wednesday, and U.S. index futures were flat, treading water after a quiet overnight session, ahead of today''s FOMC minutes which some hope will unveil more detail on the Fed''s upcoming rate hike and QT, while also weighing the risks from the Ukraine tensions against inflation and tighter monetary policy. S&P 500 futures were flat and Nasdaq futures were little changed by 7:15 a.m. in New York, trimming earlier gains after NATO Sec. Stoltenberg pushed back on claims of Russian troop withdrawals, adding he is yet to see signs of a de-escalation. Treasury yields, bitcoin, gold and the dollar were also all flat. Oil recovered after the biggest one-day loss this year as worries about potential disruptions to commodity supplies eased. Making a mockery of the Deep State/CIA/CNN which predicted that a Russian invasion would take place today, the Russian defense ministry announced more troops were returning to their bases after maneuvers ended in Crimea, while western officials remained cautious.

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following Amended HIV Study Agreem

PacBio (PACB) sees strength in Q4 segmental revenues, led by robust consumable and instrument sales.

Pacific Biosciences of California Inc (NASDAQ: PACB ) reported Q4 sales of $36.02 million , +33% Y/Y, missing the consensus of $36.12 million. The company placed 48 Sequel II or IIe instruments in the quarter, bringing the total installed base to 374, compared to 203 a year … Full story available on Benzinga.com

PACB earnings call for the period ending December 31, 2021.

PACB earnings call for the period ending December 31, 2021.

Pacific Biosciences (PACB) delivered earnings and revenue surprises of -7.14% and 0.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Pacific Biosciences of California, Inc. (PACB) CEO Christian Henry on Q4 2021 Results - Earnings Call Transcript